OBJECTIVES: V116 is a 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes eight unique serotypes (15A, 15C [from de-O-Ac-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine. According to 2019 data from Switzerland, the serotypes covered by V116 were responsible for approximately 78% of invasive pneumococcal disease (IPD) compared to 70% in PCV20, and the unique 8 serotypes in V116 were responsible for approximately 15%. This study estimates the potential health and economic impact of vaccination with V116 vs. PCV20 on IPD amongst adults aged 50+ in Switzerland.

METHODS: A Markov model estimated the lifetime IPD cases, IPD related deaths, and the associated direct medical costs (2023 CHF) among adults aged 50-64 and 65+ vaccinating with V116 or PCV20. The same serotype specific vaccine effectiveness, and the same vaccine coverage rates (60%) were assumed for the two vaccines

RESULTS: In adults aged 50-64, V116 prevented 2,699 IPD cases and 256 IPD deaths – 22% more than the 2214 IPD cases and 210 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in ~CHF33 million reduction in direct IPD medical costs, higher than the ~CHF28 million costs averted by PCV20.

In adults aged 65+, V116 prevented 2,478 IPD cases and 297 IPD deaths – 22% more than the 2,033 IPD cases and 244 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in ~CHF29 million reduction in direct IPD medical costs, higher than the ~CHF24 million costs averted by PCV20.

CONCLUSIONS: V116 led to a greater reduction (compared to PCV20) of both the health and economic burden associated with IPD among adults aged 50+ years in Switzerland.